T257 PILL – IDENTIFICATION, MECHANISM OF ACTION, SIDE EFFECTS

Pill Identification & Overview

A white to off-white, capsule-shaped (oblong) tablet debossed with “T 257” on one face and featuring a single score line (bisect) on the reverse is Hydrocodone Bitartrate and Acetaminophen 5 mg / 325 mg. It is a generic formulation equivalent to the brand-name medication Norco 5/325 (and related brand names such as Vicodin and Lortab).

Characteristic – Specification

• Active Ingredients – Hydrocodone Bitartrate (5 mg) + Acetaminophen (325 mg)
• Drug Class – Opioid Analgesic / Non-Opioid Analgesic Combination
• Color & Shape – White to off-white, capsule-shaped / oblong tablet
• Imprint / Markings – Debossed with “T 257” on one side; plain with bisect line on reverse
• Scoring – Bisected (scored)
• Distributor / Manufacturer – Camber Pharmaceuticals, Inc. / Ascent Pharmaceuticals, Inc.
• Controlled Status – Schedule II (C-II) Controlled Substance (Prescription only)

Mechanism of Action (Pharmacology)

The T 257 pill achieves analgesia through two synergistic, complementary mechanisms:

• Hydrocodone (Semisynthetic Opioid): Hydrocodone is a full opioid receptor agonist. Upon binding to opioid receptors located throughout the central nervous system (CNS) and spinal cord, it inhibits adenylate cyclase, closes voltage-gated calcium channels, and opens inwardly rectifying potassium channels. This hyperpolarizes neurons, suppressing the transmission of ascending nociceptive (pain) signals to higher brain centers and altering the emotional perception of pain.
• Acetaminophen (Non-Opioid Analgesic & Antipyretic): Acetaminophen provides complementary central analgesia primarily by inhibiting central prostaglandin synthesis through the cyclooxygenase pathways (particularly variants) and activating descending serotonergic inhibitory pathways.

Therapeutic Indications & Dosage

Approved Clinical Indications

• Moderate to Moderately Severe Pain: Indicated for the management of acute pain severe enough to require an opioid analgesic when alternative, non-opioid pain treatments are inadequate or not tolerated (e.g., post-operative recovery, severe acute musculoskeletal trauma, dental surgeries).

Dosage & Administration

• Standard Adult Dosing:
• 1 to 2 tablets administered orally every 4 to 6 hours as needed for pain.

• Maximum Daily Limits:
• Total hydrocodone dosage is adjusted to clinical response, but daily intake of acetaminophen must not exceed 4,000 mg (4 grams) in a 24-hour period from all sources to avoid catastrophic liver toxicity.
• In clinical practice, many clinicians cap daily acetaminophen at 3,000 mg/day for long-term or vulnerable patients.
• Therefore, the maximum daily intake of T 257 tablets is typically limited to no more than 8 tablets in 24 hours.

• Administration: May be taken with or without food. Taking it with food or milk helps reduce potential nausea or gastric upset.

Side Effects Profile

Common Side Effects

• Lightheadedness, dizziness, and sedation
• Nausea and vomiting
• Constipation (due to opioid-induced reduction in gastrointestinal motility)
• Somnolence and mental clouding
• Pruritus (itching) or mild sweating

Serious Adverse Reactions (Require Immediate Medical Attention)

• Life-Threatening Respiratory Depression: Severely slowed, shallow, or irregular breathing.
• Acute Hepatotoxicity: Liver injury or acute liver failure, almost exclusively resulting from exceeding daily acetaminophen limits or combining with alcohol.
• Severe Hypotension & Syncope: Significant drops in blood pressure upon standing.
• Adrenal Insufficiency: Fatigue, weakness, nausea, and low blood pressure following prolonged opioid exposure.
• Severe Allergic Reactions (Anaphylaxis): Swelling of the throat, tongue, or face, severe hives, and difficulty breathing.

Precautions & Drug Interactions

• Concomitant Acetaminophen Products: Patients must be counseled never to combine T 257 with over-the-counter cold, flu, cough, or headache medications containing acetaminophen (e.g., Tylenol, DayQuil, NyQuil, Excedrin) to prevent accidental hepatotoxic overdose.
• CYP3A4 & CYP2D6 Interactions: Hydrocodone is metabolized in the liver via CYP3A4 and CYP2D6 enzymes. Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) increase hydrocodone plasma levels and toxicity risk, whereas CYP3A4 inducers (e.g., rifampin, carbamazepine) decrease analgesic efficacy.
• Serotonergic Drugs: Co-administration with SSRIs, SNRIs, tricyclic antidepressants, or MAOIs can trigger serotonin syndrome.
• Gastrointestinal & Biliary Disease: Opioids can cause spasm of the sphincter of Oddi and obscure diagnoses in acute abdominal conditions.
• Physical Dependence & Tolerance: Prolonged use leads to physiologic adaptation. Discontinuation after extended use must involve a gradual taper to prevent acute withdrawal syndrome (restlessness, lacrimation, rhinorrhea, sweating, chills, myalgia, severe anxiety).

Boxed Warnings & Critical Safety Information

FDA Black Box Warnings

• Addiction, Abuse, and Misuse: Hydrocodone exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient’s risk prior to prescribing.
• Life-Threatening Respiratory Depression: Serious, life-threatening, or fatal respiratory depression may occur with the use of hydrocodone. Carbon dioxide retention from respiratory depression can exacerbate intracranial pressure.
• Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants: Concomitant use of opioids with benzodiazepines, other sedatives, or alcohol can result in profound sedation, respiratory depression, coma, and death.
• Hepatotoxicity: Acetaminophen has been associated with cases of acute liver failure, sometimes resulting in liver transplant or death, typically at dosages exceeding 4,000 mg/day or when combined with alcohol.
• Accidental Ingestion: Accidental ingestion of even one dose, especially by children, can result in a fatal overdose of hydrocodone.
• Neonatal Opioid Withdrawal Syndrome (NOWS): Prolonged maternal use during pregnancy can cause life-threatening withdrawal in the newborn.

• Counterfeit Alert: Oblong hydrocodone tablets (like “T 257”, “M365”, and “M367”) are among the most frequently replicated pills on illicit drug markets. Illicit counterfeit presses often contain lethal quantities of illicit fentanyl or novel synthetic opioids. Tablets must only be dispensed through licensed, verified pharmacies.